DD 2015.jpg

Don DeGolyer – President & Chief Executive Officer

Don DeGolyer is the President & Chief Executive Officer of Vertice Pharma and has built a successful and significant career in the pharmaceutical industry.  He was previously the Chief Operating Officer of Endo Pharmaceuticals where he built one of the fastest growing Specialty Pharmaceuticals businesses, completed six acquisitions and created more than $12 Billion dollars of shareholder value. He also served as President & CEO of Sandoz North America at a time when he and his team grew revenues to $3.5 billion establishing Sandoz as the second largest generics company in the world. Don began his career at Pfizer, Johnson & Johnson and then Novartis progressing through various roles of increasing responsibility.  






Andrew Saik – Chief Financial Officer

Andrew is the Chief Financial Officer of Vertice Pharma and has 20 years of hands-on experience, including developing and driving financial strategy, integrating global company and product acquisitions, cash management, general ledger, SOX compliance, manufacturing, supply chain, research and development, managed care, and financial planning and analysis. 

Andrew was most recently Chief Financial Officer for Auxilium Pharmaceuticals and played a critical leadership role in executing Auxilium's diversification and growth strategy. Prior to joining Auxilium, Mr. Saik was SeniorVice President, Finance and Treasurer at Endo Health Solutions, where he was responsible for internal and external reporting, global consolidations M&A transactions, cash management, debt financing and risk management. During his tenure at Endo, he helped complete the $1.6 billion acquisition of Paladin Labs and refinanced $3 billion into debt in a new corporate structure.

Scott Meyers

Scott Meyers - Chief Operating Officer

Scott Meyers is the Chief Operating Officer of Vertice Pharma.  He has over 15 years of pharmaceutical experience, most recently as Vice President, General Manager, Dermatology of Fougera Inc., a Sandoz / Novartis company.   Prior to Fougera, Scott led Strategic Planning & Market Analytics for Sandoz US and worked at McKinsey & Company’s pharmaceutical practice in New Jersey, focusing on R&D and commercial operations.  Scott also worked as a Chemical Engineer for Merck at their West Point, PA site. Scott holds a Master of Business Administration from Northwestern University’s Kellogg School of Management and holds a Master of Chemical Engineering, a Bachelor of Science in Chemical Engineering, and a Bachelor of Arts in Chemistry all from Cornell University.


Árpád Széchényi Vice President, Commercial Operations

Árpád Széchényi is the Vice President, Commercial Operations of Vertice Pharma. He previously worked for Sandoz U.S. where he and his team grew new products to a $350m business and more than doubled Sandoz’s annual launch performance.

Prior to Sandoz, Árpád worked at McKinsey & Company's pharmaceuticals practice in New York, Dubai, Tokyo and Berlin, focusing on branded and generic marketing and commercial operations. Árpád holds a master in business administration and a master of arts in philosophy from the University of Munich. 



Dr. Nandi is the Vice President, Research & Development at Vertice Pharma and has over 15 years of experience in R&D. Dr. Nandi was most recently Vice President, Generic Research & Development for Impax Laboratories where he was responsible for CMC development activity for Generic and Branded pipeline. Prior to Impax, Dr. Nandi held positions of increasing responsibilities at Sandoz, including last position as Executive Director, Portfolio, Project Management and Scientific Affairs. He also worked in various positions in R&D at Par Pharmaceuticals and Geneva Pharmaceuticals. Dr. Nandi has hands-on experience in Product Development of ANDA including First to File and 505 (b)(2) products in various dosage forms and also extensive experience in Portfolio & Project Management, Development Operations, Licensing, Due Diligence, Remediation Programs and R&D Strategy. He co-authored various scientific publications and patents and patent applications. Dr. Nandi also delivered invited talks in the area of drug delivery and generic portfolio and project management strategy in various national and international symposiums. He holds a Master of Business Administration from Rutgers, State University of NJ; a Ph.D. in Pharmaceutical Sciences from St. John’s University, NY and a Master’s degree in Pharmacy from Birla Institute of Technology and Sciences, India.


George Schwab is the Vice President, Quality of Vertice Pharma.  He has over 25 years of experience in the Pharmaceutical Industry and has held leadership positions in both Quality and Regulatory Compliance for multiple domestic and global pharmaceutical manufacturers. Most recently, he was the Head of Quality for Fougera Inc. (a Sandoz Company) where he oversaw all quality and compliance activities for the organization.  Prior to his time at Fougera, he was the Head of Quality for Novel Laboratories/ Gavis Pharmaceuticals in Somerset N.J.  He also held leadership positions at Barr Laboratories, Pliva Inc. and Lederle Laboratories.

 George holds a Master of Science degree in Applied Chemistry from New Jersey Institute of Technology,  as well as a MBA in Pharmaceutical Business from Fairleigh Dickenson University.  George is also a past Chairman of the Board for the New Jersey Pharmaceutical Quality Control Association (NJPQCA/2012-13) and holds a Pharmaceutical GMP Professional Certification from the American Society for Quality (ASQ).